The field of mesenchymal stem cell research (MSC) has been rapidly expanding in recent years, bringing to market new concepts for treatments and applications. Indeed, MSCs are now one of the most commonly pursued stem types for clinical purposes.
Therefore, this post considers the top ten most frequently shared MSC articles over a 12 month period. The purpose of this analysis is to determine the type of MSC content that is most widely shared across social media platforms, as well as the authors and publishers of these articles.
Methodology for Determining the Top 10 MSC Articles
The top ten most shared mesenchymal stem cell articles are listed below. The share data is generated using Facebook, LinkedIn, Twitter, Google+, and Pinterest shares, and has been aggregated using the service BuzzSumo.com, a social analytics tool that is designed to assist content marketers and SEO specialists with discovering engaging content opportunities.
While the platform was not originally designed for market research purposes, it is an incredible business intelligence (BI) tool.
Interestingly, Facebook shares consistently contribute the largest number of social shares for MSC-related articles.
“Clinical Trials for MS and Rheumatoid Arthritis with Umbilical Cord Mesenchymal Stem Cells”, released on YouTube last November, wins first place as the most shared MSC article over the past 12 months. In total, it generated an impressive 7,400 shares.
“Mesenchymal Stem Cells Aggregate and Deliver Gold Nanoparticles to Tumors for Photothermal Therapy” wins second place, although it follows substantially behind, producing only 3,300 shares.
“Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential” wins third place, receiving over 2,000 shares over the past 12 months.
Full results for the top 10 most shared MSC articles are shown in the table below.
TABLE: Top 10 Most Shared MSC Articles over a 12-Month Period
Want to be better informed than your competition? Get future stem cell industry updates.
About Us
BioInformant is the only research firm that has served the stem cell sector since it emerged. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Medical Ethics, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.
To learn more about this market segment, view the global strategic report “Mesenchymal Stem Cells – Advances & Applications.”